Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders

Vertex Pharmaceuticals (VRTX) and partner CRISPR Therapeutics (CRSP) announced that the European Commission has granted conditional marketing approval to their one-shot gene therapy Casgevy for treating two debilitating blood disorders, sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).Casgevy is approved for patients 12 years and older with severe SCD characterized by recurrent vaso-occlusive crises (VOCs) or TDT, for whom hematopoietic stem cell (HSC) transplantation is appropriat ...